Weekly Analysts’ Ratings Changes for Cabaletta Bio (CABA)

A number of firms have modified their ratings and price targets on shares of Cabaletta Bio (NASDAQ: CABA) recently:

• 4/1/2025 – Cabaletta Bio had its price target lowered by analysts at Morgan Stanley from $30.00 to $22.00. They now have an “overweight” rating on the stock.
• 4/1/2025 – Cabaletta Bio had its price target lowered by analysts at Wells Fargo & Company from $6.00 to $3.00. They now have an “equal weight” rating on the stock.
• 4/1/2025 – Cabaletta Bio had its price target lowered by analysts at UBS Group AG from $10.00 to $7.00. They now have a “buy” rating on the stock.
• 4/1/2025 – Cabaletta Bio had its “buy” rating reaffirmed by analysts at Guggenheim. They now have a $23.00 price target on the stock.
• 4/1/2025 – Cabaletta Bio had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
• 2/18/2025 – Cabaletta Bio had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.

Cabaletta Bio Price Performance

Shares of CABA traded up $0.08 during trading hours on Wednesday, hitting $1.25. The stock had a trading volume of 780,687 shares, compared to its average volume of 1,489,799. Cabaletta Bio, Inc. has a 12 month low of $1.16 and a 12 month high of $19.04. The stock has a fifty day moving average price of $2.06 and a 200 day moving average price of $2.93. The firm has a market capitalization of $61.10 million, a PE ratio of -0.58 and a beta of 2.58.

Hedge Funds Weigh In On Cabaletta Bio

Institutional investors and hedge funds have recently made changes to their positions in the business. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Cabaletta Bio in the 3rd quarter worth approximately $32,000. Point72 DIFC Ltd purchased a new stake in Cabaletta Bio in the 3rd quarter worth $33,000. Miller Financial Services LLC purchased a new position in shares of Cabaletta Bio in the fourth quarter valued at $33,000. Avanza Fonder AB purchased a new position in shares of Cabaletta Bio in the 4th quarter worth $40,000. Finally, Intech Investment Management LLC boosted its holdings in shares of Cabaletta Bio by 42.2% in the 4th quarter. Intech Investment Management LLC now owns 20,203 shares of the company’s stock worth $46,000 after purchasing an additional 5,999 shares during the period.

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.